НовостиBenzingaRoth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35 Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35 Benzinga 2026.10.05 17:09 (GMT+0) Открыть на Benzinga Другие новости